Upstream Bioprocessing Market to Notice a CAGR 13.4% | 2030

Upstream Bioprocessing Market Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Bioreactors/Fermenters, Cell Culture, Filters, Bags and Containers, and Others), Workflow (Media Preparation, Cell Culture, and Cell Separation), Usage Type (Single Use and Multiuse), Mode (In-House and Outsourced), and Geography

Publication Month : Jan 2024

  • Report Code : TIPRE00006819
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 210
Inquire Before Buy

PRICING

$5190

$4152

[Research Report] The upstream bioprocessing market value is projected to grow from US$ 9,174.09 million in 2022 to US$ 25,046.69 million by 2030. The upstream bioprocessing market is further anticipated to record a CAGR of 13.4% from 2022 to 2030.

Market Insights and Analyst View:

Upstream bioprocessing, the first stage of bioprocessing, includes cell line development, media development, and cultivation. Key factors driving the upstream bioprocessing market growth include the commercial use of single-use bioreactors, outsourcing of biopharmaceutical manufacturing, and rapid growth of pharmaceutical and biotechnology industries. However, a stringent regulatory framework hinders the upstream bioprocessing market growth.  

Growth Drivers and Restraints:

Various manufacturers are developing single-use bioreactors (SUBs) due to their robust build and high performance, which are necessary for the commercial manufacturing of biopharmaceuticals. Incorporating technologies associated with biofilm formation, stirring mechanisms, bioreactor designs, and sensor systems, among others, have increased the adoption of disposable reactors at the laboratory and production scales. Single-use bioreactors are operated to manufacture next-generation cell and gene therapies, and they are suitable for continuous bioprocessing. Advancements in cell-culture processes now enable the development of higher titers and cell densities, which indicate a large scope for the adoption of SUBs. Single-use bioreactors operate with a low risk of contamination, shorter production turnaround times, and reduced validation time. In the last few years, the use of single-use bioreactors has increased in modern biopharmaceutical processes owing to their unique ability to aid enhanced flexibility, reduce investments, and limit operational costs. Also, many companies have developed single-use bioreactors for producing a wide range of therapeutics. In March 2021, Thermo Fischer Scientific launched the HyPerforma DynaDrive single-use bioreactors with 3,000 L and 5,000 L capacities. Sartorius AG offers a wide range of single-use bioreactors. The company provides ambr 15 for a 10–15 mL micro bioreactor scale and Biostat STR for 50–2,000L. The use of single-use bioreactors is subsequently increasing in upstream bioprocessing. Thus, the increasing acceptance of single-use bioreactors for the production of therapeutics propels the upstream bioprocessing market.

Regulatory authorities such as the Food & Drug Administration and the European Medicine Agency (EMA) monitor the operations of pharmaceutical manufacturers with consistent stringency. These businesses are thus bound to abide by the updated regulations promoting current good manufacturing practices (cGMP) and good laboratory practices (GLP) for assuring the control and monitoring of manufacturing processes and facilities. Currently, the FDA's CBER regulations do not mention single‑use bioreactors. Any diversions from the registered protocols, demands, and requirements of this guidance may lead to the termination of the clinical trials orchestrated by manufacturers or outsourced organizations. Although the stringent regulations associated with the biotechnology industry bolster the demand for bioreactors, the lack of well-defined regulatory frameworks in developing nations such as China, India, and Brazil hinders the overall growth of the upstream bioprocessing market growth.

The molecules obtained from bioprocessing may not generate the same results in clinical trials as in laboratory environments, which is another significant concern associated with the use of SUBs. The mixing mechanisms of SUBs may also lead to difficulties adhering to regulations, which restricts their use. For instance, in wave-type SUBs, the mixing principle is limited to a rocking movement, leading to uneven mixing and causing errors. Hence, the safety and efficacy of biologics may raise significant concerns in the application of SUBs.

Trends:

Increasing investments in research and development (R&D) in the biopharmaceutical industry are likely to bring new trends into the upstream bioprocessing market in the coming years. In March 2020, Culture Biosciences announced securing the funds of US$ 15 million (€13.4 million) in the Series A investment round, citing the backing of new and existing venture capital backers. According to Culture Biosciences, the money has been used to treble the capacity of bioreactors as well as to develop more cloud-based software monitoring and development tools for biomanufacturing research and development. The company states that this investment will help scientists manage their whole R&D workflow via software applications, hence supporting the digitization of biomanufacturing R&D.

As R&D investments continue to surge, particularly in novel biologics, advanced therapies, and personalized medicine, there is a parallel emphasis on optimizing upstream bioprocessing technologies and methodologies. This trend is leading to the development of innovative bioreactor systems, cell culture media formulations, and process automation solutions to enhance biopharmaceutical production operations' efficiency, scalability, and productivity. Furthermore, the focus on R&D investments favors the development of cutting-edge bioprocessing platforms that cater to the evolving biopharmaceuticals landscape, including next-generation therapeutic modalities and biosimilars. Additionally, dedicating R&D funds for bioprocessing trends such as continuous bioprocessing and advanced analytics for process monitoring is expected to reshape the future of upstream bioprocessing, driving the adoption of state-of-the-art technologies and establishing new benchmarks for process performance, quality, and regulatory compliance.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Upstream Bioprocessing Market: Strategic Insights

upstream-bioprocessing-market
Market Size Value inUS$ 9,174.09 million in 2022
Market Size Value byUS$ 25,046.69 million by 2030
Growth rateCAGR of 13.4% from 2022 to 2030
Forecast Period2022-2030
Base Year2022
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

The upstream bioprocessing market is segmented on the basis of product type, workflow, usage type, and mode. Based on product type, the market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. In terms of workflow, the market is differentiated into media preparation, cell culture, and cell separation. The upstream bioprocessing market, by usage, is divided into single-use and multi-use. Based on mode, the upstream bioprocessing market is bifurcated into in-house and outsourced. In terms of geography, the upstream bioprocessing market is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Russia, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Segmental Analysis:

The bioreactors/fermenters segment held the largest share of the upstream bioprocessing market, based on product type, in 2022. The cell culture segment is anticipated to register a significant CAGR in the market during 2022–2030. Bioreactors and fermenters serve as core vessels in which cells and microorganisms are grown for various therapeutic and bioprocessing applications involving the expression and production of biologically derived compounds. These systems are engineered to provide an optimal environment for cell growth, incorporating precise control over parameters such as temperature, pH, dissolved oxygen, and agitation. These parameters are critical for cultivating cells and microorganisms in large-scale bioprocessing operations.

Upstream Bioprocessing Market, by Product Type – 2022 and 2030

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Based on workflow, the upstream bioprocessing market is classified into media preparation, cell culture, and cell separation. The cell separation segment held the largest share of the upstream bioprocessing market in 2022. The same segment is further anticipated to record a significant CAGR in the market from 2022 to 2030. Cell separation is the initial stage of segregating protein products (cells) from the culture. The amount and quality of the product collected in bioreactors play a pivotal role in the decision-making regarding the discontinuation of a cell culture.

Based on usage type, the global upstream bioprocessing market is classified into single use and multiuse. The single use segment held a larger share of the market in 2022. The market for this segment is expected to grow at a significant CAGR during 2022–2030. The upstream bioprocessing market has experienced a transformative shift with the widespread adoption of single-use technologies. Single-use systems, including bioreactors, bags, and connectors, have gained prominence for their flexibility, cost-effectiveness, and reduced risk of cross-contamination. These disposable components replace traditional stainless-steel equipment, offering a more agile and scalable approach to bioproduction. The single-use trend accelerates process development, minimizes cleaning and validation efforts, and facilitates quick changeovers between production runs.

The upstream bioprocessing market is segmented into in-house and outsourced based on mode. In 2022, the in-house segment held a larger market share. The outsourced segment is expected to record a higher CAGR during 2022–2030. In-house manufacturing is gaining traction in the upstream bioprocessing market as biopharmaceutical companies seek greater control over their production processes. Establishing in-house upstream bioprocessing facilities enables companies to tailor processes to their needs, ensuring a more customized and efficient approach. This strategy often involves investment in state-of-the-art bioreactors, cell culture systems, and associated technologies.

Regional Analysis:

The upstream bioprocessing market, based on region, is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America held the largest share of the global upstream bioprocessing market. Asia Pacific is estimated to register the highest CAGR during 2022–2030.

The US is the largest market for bioreactors—several market players in the US manufacture bioreactors for pharmaceutical and biotechnology companies. Launch of new bioreactors, geographic expansion strategies, and partnerships among market players bolster the upstream bioprocessing market growth in the US. In April 2023, BioMADE announced 5 new projects focused on addressing gaps in research and the adoption of bioreactors in bioindustrial manufacturing in the US. With a funding commitment of US$ 10.5 million, these projects would span engineering, hardware development, and scalability to address difficulties associated with the economies of scale. These projects would focus on innovation to introduce advanced bioreactor designs supported by Schmidt Futures. In April 2023, Cytiva launched X-platform bioreactors to simplify upstream bioprocessing operations with single-use products. Initially, bioreactors were available in 50 L and 200 L sizes. The X-Platform bioreactors are equipped with Figurate automation solution software, and they can increase process efficiency through ergonomic improvements, production capacity, and simplified supply chain operations.

The growth of the biopharmaceutical sector, mainly due to technological advancements, increasing flexibility, and low operational costs, also benefits the upstream bioprocessing market in the US. As per the International Trade Administration (ITA), the US is the largest market for biopharmaceuticals, and it is also the global leader in biopharmaceutical R&D. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), companies in the US account for nearly 50% of the global pharmaceutical R&D work, and they have succeeded in developing many novel medicines for which they hold intellectual property rights. A continuous increase in the development of new biologics, resulting in the approval of more new molecular entities (NME) by regulatory authorities, creates opportunities for the growth of the upstream bioprocessing market in the US. According to the Chemical & Engineering News, the US Food and Drug Administration (FDA) approved ~37, 50, and 53 new NMEs in 2022, 2021, and 2020, respectively. Furthermore, increasing R&D investments by US-based pharmaceutical and biotechnology companies to improve outcomes of clinical trials and ensure patient safety contributes to the growth of the upstream bioprocessing market in the US. The subsequently growing traction toward precision medicine with rising investments by the US government is likely to contribute to market growth in the coming years.

Industry Developments and Future Opportunities:

Different initiatives by prominent players in the global upstream bioprocessing market are listed below:

  1. In December 2023, Merck acquired Erbi Biosystems, a Massachusetts-based company that developed the "Breez" 2 ml micro-bioreactor platform technology. The purchase boosts Merck's upstream therapeutic protein portfolio, enabling it to promptly develop lab-scale protocols for scalable cell-based perfusion bioreactor processes with capacities ranging from 2 ml to 2000 l. Additionally, it offers opportunities for further study and advancement in cutting-edge modality applications, like cell therapies.
  2. In October 2023, Getinge AB acquired High Purity New England, Inc. for US$ 120 million. By the end of 2024, the company will fully integrate High Purity New England, Inc. The acquisition has helped Getinge AB acquire a comprehensive range of proprietary and distributed products from drug discovery, upstream and downstream processing, and fill-and-finish.
  3. In January 2023, Sartorius collaborated with RoosterBio Inc. to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) - based exosome production platform that delivers industry-leading yield, purity, and potency.
  4. In February 2022, Thermo Fisher Scientific In announced an expansion for its Bioprocessing. The company has invested US$40 million to construct and maintain a manufacturing plant for single-use technologies in Millersburg, Pennsylvania. The expansion was part of a multi-year, US$ 650 million investment to improve the company's capacity to produce bioprocessing in a flexible, scalable, and dependable manner.
  5. In March 2021, Thermo Fisher Scientific Inc launched HyPerforma DynaDrive S.U.B. in different volumes, 3,000 L and 5,000 L models. Thermo Fisher Scientific's largest commercially accessible S.U.B., the first-of-its-size 5,000 L S.U.B., allows biopharmaceutical businesses to incorporate single-use technologies into large-scale bioprocesses, such as cGMP manufacture at very high cell density and perfusion cell culture.

Competitive Landscape and Key Companies:

Thermo Fisher Scientific Inc, Esco Micro Pte Ltd, Cellexus International Ltd, Sartorius AG, Danaher Corp, Getinge AB, Merck KGaA, Corning Inc, Entegris Inc, and PBS Biotech Inc are among the prominent players operating in the upstream bioprocessing market. These companies focus on the development and adoption of new technologies, advancements in existing products, and expansion of their geographic presence to meet the growing consumer demand worldwide.  

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Product Type, Workflow, Usage Type, Mode, and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which mode segment dominates the upstream bioprocessing market?

Based on mode, the upstream bioprocessing market is segmented into in-house and outsourced. In 2022, the in-house segment held a larger market share. The outsourced segment is expected to record a higher CAGR during 2022–2030.

Which usage type segment dominates the upstream bioprocessing market?

The global upstream bioprocessing market, based on usage type, is classified into single use and multiuse. The single use segment held a larger share of the market in 2022. The same segment is anticipated to record a significant CAGR in the upstream bioprocessing market during 2022–2030.

Which workflow segment dominates the upstream bioprocessing market?

Based on workflow, the upstream bioprocessing market is classified into media preparation, cell culture, and cell separation. The cell separation segment held the largest share of the upstream bioprocessing market in 2022. It is further anticipated to register a significant CAGR from 2022 to 2030.

What are the growth estimates for the upstream bioprocessing market till 2030?

The upstream bioprocessing market is expected to be valued at US$ 25,046.69 million in 2030.

Which product type segment dominates the upstream bioprocessing market?

The upstream bioprocessing market, based on product type, is segmented into bioreactors and fermenters, cell culture media, filters, bags and containers, and others. The bioreactors/fermenters segment held the largest share of the upstream bioprocessing market in 2022. Moreover, the cell culture segment is anticipated to register a significant CAGR during 2022–2030.

What was the estimated upstream bioprocessing market size in 2022?

The upstream bioprocessing market was valued at US$ 9,174.09 million in 2022.

Who are the major players in the upstream bioprocessing market?

The upstream bioprocessing market majorly consists of the players, including Thermo Fisher Scientific Inc, Esco Micro Pte Ltd, Cellexus International Ltd, Sartorius AG, Danaher Corp, Getinge AB, Merck KGaA, Corning Inc, Entegris Inc, and PBS Biotech Inc.

What is upstream bioprocessing?

Upstream bioprocessing is the first stage of the bioprocess. Upstream phase includes processes such as cell line development, media development and cultivation.

What factors drive the upstream bioprocessing market?

Factors such as the commercial use of single-use bioreactors, outsourcing of biopharmaceutical manufacturing, and rapid growth of pharmaceutical and biotechnology industries propel market growth.

The List of Companies - Upstream Bioprocessing Market 

  1. Thermo Fisher Scientific Inc         
  2. Esco Micro Pte Ltd          
  3. Cellexus International Ltd            
  4. Sartorius AG       
  5. Danaher Corp     
  6. Getinge AB         
  7. Merck KGaA       
  8. Corning Inc         
  9. Entegris Inc         
  10. PBS Biotech Inc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Upstream Bioprocessing Market